Biotest Aktiengesellschaft

WBAG:BIO3 Stock Report

Market Cap: €1.4b

Biotest Past Earnings Performance

Past criteria checks 3/6

Biotest has been growing earnings at an average annual rate of 49.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 11.7% per year. Biotest's return on equity is 30.7%, and it has net margins of 21%.

Key information

49.2%

Earnings growth rate

49.8%

EPS growth rate

Biotechs Industry Growth14.8%
Revenue growth rate11.7%
Return on equity30.7%
Net Margin21.0%
Next Earnings Update08 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biotest makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WBAG:BIO3 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 247811648765
31 Mar 247831778671
31 Dec 236851278467
30 Sep 236831198456
30 Jun 23538-108557
31 Mar 23517-478450
31 Dec 22516-328251
30 Sep 22505-698451
30 Jun 22511-658350
31 Mar 22512-548251
31 Dec 21516-638252
30 Sep 21514-287755
30 Jun 21507-337855
31 Mar 21507-358056
31 Dec 20484-318056
30 Sep 20466-348256
30 Jun 20459-248454
31 Mar 20439-158352
31 Dec 19419-58353
30 Sep 19406-98252
30 Jun 19395-38253
31 Mar 19390-68251
31 Dec 18400-138549
30 Sep 18405189150
30 Jun 1840969152
31 Mar 1840019954
31 Dec 17378-1610055
30 Sep 17257-489556
30 Jun 17301-479352
31 Mar 17340-298949
31 Dec 1640868848
30 Sep 165311287836
30 Jun 16525528862
31 Mar 16526368872
31 Dec 15535279379
30 Sep 15590-8810793
30 Jun 15606310973
31 Mar 156021611069
31 Dec 145821910867
30 Sep 145432710572
30 Jun 14522319869
31 Mar 14504309567
31 Dec 13501329365

Quality Earnings: BIO3 has high quality earnings.

Growing Profit Margin: BIO3 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIO3 has become profitable over the past 5 years, growing earnings by 49.2% per year.

Accelerating Growth: BIO3 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BIO3 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: Whilst BIO3's Return on Equity (30.68%) is high, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies